


# ASCENT-04: A Randomized, Open-Label, Phase 3 Study of Sacituzumab Govitecan (SG) and Pembrolizumab Versus Treatment of Physician's Choice (TPC) and Pembrolizumab in Patients With Previously Untreated, Locally Advanced, Inoperable, or Metastatic Triple Negative Breast Cancer Whose Tumors Express PD-L1<sup>a</sup>

## Study Design<sup>1,2</sup>



## Enrollment

### Study Population 1L mTNBC

- Previously untreated, locally advanced, unresectable or de novo mTNBC
- PD-L1+ by 22C3 CPS  $\geq 10$
- $\geq 6$  months since treatment in curative setting
- Prior aPD-(L)1 use allowed in the curative setting
- PD-L1 and TNBC status centrally confirmed

## Key Eligibility Criteria<sup>1,2</sup>

### Key Inclusion Criteria

- $\geq 18$  years of age
- ECOG PS of 0 or 1
- Adequate renal and hepatic function
- Patients with locally advanced, inoperable, or mTNBC who have not received previous systemic therapy for advanced disease and whose tumors are PD-L1 positive at screening. Patients presenting with de novo mTNBC are eligible
- At least 6 months must have elapsed between completion of treatment with curative intent and first documented local or distant disease recurrence

### Key Exclusion Criteria

- Positive serum pregnancy test or women who are lactating
- Active CNS metastases and/or carcinomatous meningitis
- No prior systemic anticancer treatment (with the exception of endocrine therapy) within the previous 6 months or radiation therapy within 2 weeks prior to enrollment

## Endpoints<sup>1,2</sup>

### Primary Endpoint

- PFS<sup>d</sup>

### Secondary Endpoints

- OS
- ORR<sup>d</sup>
- DOR<sup>d</sup>
- TTR<sup>d</sup>
- PROs
- Safety

<sup>a</sup>In collaboration with Merck.

<sup>b</sup>Maximum 35 cycles of pembrolizumab (Arm A) or TPC (Arm B).

<sup>c</sup>Crossover to SG in eligible patients allowed after BICR-verified disease progression.

<sup>d</sup>By BICR using RECIST v1.1

1L, first line; ADC, antibody-drug conjugate; aPD-(L)1, anti-programmed death-(ligand) 1; AUC, area under the curve; BICR, blinded independent central review; CNS, central nervous system; CPS, combined positive score; DOR, duration of response; ECOG, Eastern Cooperative Oncology Group; IV, intravenous; mTNBC, metastatic TNBC; ORR, objective response rate; OS, overall survival; PD-L1, programmed death ligand 1; PFS, progression-free survival; PRO, patient-reported outcome; PS, performance status; RECIST, Response Evaluation Criteria in Solid Tumors; SG, sacituzumab govitecan; TNBC, triple-negative breast cancer; TTR, time to onset of response.

### References

1. Clinicaltrials.gov website. Accessed May 3, 2024. <https://clinicaltrials.gov/ct2/show/NCT05382286>
2. Data on file. Gilead Sciences, Inc.; 2022.

**The safety and efficacy of these investigational agents have not been established, and they have not received marketing authorization in this setting. There is no guarantee that these investigational agents and/or uses will receive Health Authority approval and/or become commercially available.** Visit [clinicaltrials.gov](https://clinicaltrials.gov) for more information. Clinicaltrials.gov: NCT05382286